Atea Pharmaceuticals Net Income Over Time
| AVIR Stock | USD 4.02 0.08 1.95% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Atea Pharmaceuticals Performance and Atea Pharmaceuticals Correlation. Can Pharmaceuticals industry sustain growth momentum? Does Atea have expansion opportunities? Factors like these will boost the valuation of Atea Pharmaceuticals. If investors know Atea will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Atea Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 2.641 | Earnings Share (1.77) | Revenue Per Share | Quarterly Revenue Growth 2.952 | Return On Assets |
Atea Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Atea's balance sheet. Smart investors calculate Atea Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Atea Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Atea Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Atea Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Atea Pharmaceuticals and related stocks such as Voyager Therapeutics, Vanda Pharmaceuticals, and Allogene Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VYGR | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (16.3 M) | (29.7 M) | (40.2 M) | (70.7 M) | (88.3 M) | (40.8 M) | 36.7 M | (66 M) | (46.4 M) | 132.3 M | (65 M) | (74.8 M) | (71 M) |
| VNDA | (9.5 M) | (9.8 M) | (27.7 M) | (20.3 M) | 20.2 M | (39.9 M) | (18 M) | (15.6 M) | 25.2 M | 115.6 M | 23.3 M | 33.2 M | 6.3 M | 2.5 M | (18.9 M) | (21.7 M) | (20.6 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (211.5 M) | (184.6 M) | (233.5 M) | (244.8 M) | (329.8 M) | (327.3 M) | (257.6 M) | (231.8 M) | (243.4 M) |
| TRDA | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (26.5 M) | (50.1 M) | (87.5 M) | (6.7 M) | 65.6 M | 75.5 M | 79.2 M |
| PYXS | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (12.8 M) | (76 M) | (118 M) | (73.8 M) | (77.3 M) | (69.6 M) | (73.1 M) |
| HUMA | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (66.5 M) | (26.5 M) | (12 M) | (110.8 M) | (148.7 M) | (133.8 M) | (127.1 M) |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | (36.2 M) | (79 M) | (121.8 M) | (133.8 M) | (116 M) | (81.9 M) | (73.7 M) | (70 M) |
| ACHV | (8.9 M) | (14.7 M) | (21.1 M) | (31.8 M) | (26.2 M) | (16.8 M) | (20.1 M) | (10.6 M) | (12.7 M) | (16.1 M) | (14.7 M) | (32.9 M) | (41.9 M) | (29.8 M) | (39.8 M) | (35.8 M) | (34.1 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.6 M) | (10.5 M) | (32.8 M) | (19.4 M) | (24.6 M) | (10.9 M) | (21.8 M) | (26 M) | (72.1 M) | (203.7 M) | 9.3 M | (29.7 M) | (80.9 M) | (72.8 M) | (69.2 M) |
Atea Pharmaceuticals and related stocks such as Voyager Therapeutics, Vanda Pharmaceuticals, and Allogene Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Atea Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Atea Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Atea Pharmaceuticals | AVIR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 225 Franklin Street, |
| Exchange | NASDAQ Exchange |
USD 4.02
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.